Navigation Links
Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for,Psychotic Major Depression Misses Primary Endpoint

ulation and often require lengthy and expensive hospital stays. There is no FDA-approved treatment for PMD.

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated is a pharmaceutical company focused on developing drugs for treating severe psychiatric and neurological diseases. Corcept's lead product, CORLUX, is in Phase 3 clinical trials for treating the psychotic features of PMD. The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to reduce the effects of the elevated and abnormal release patterns of cortisol seen in PMD. The company has also initiated a proof-of-concept study to evaluate the ability of CORLUX to mitigate weight gain associated with the use of olanzapine. For more information, please visit www.corcept.com.

Forward-looking Statements

Statements made in this news release – other than statements of historical fact – are forward-looking statements. These include information relating to Corcept’s PMD clinical development program and the timing of the completion of Phase 3 trials. Forward-looking statements are subject to a number of known and unknown risks and uncertainties that might cause actual results to differ materially from those expressed or implied here. For example, there can be no assurances on the efficacy, safety, enrollment completion or success of clinical trials; the regulatory process or regulatory approvals; commercial success; in addition, trial timetables may not be accurate. Risk factors are explained in the company's SEC filings, all of which are available from its Web site (www.corcept.com) or from the SEC's Web site (www.sec.gov). The company does not have any intention or duty to update forward-looking statements made in this news release.


CONTACT:
Fred Kurland
Chief Financial Officer
Corcept Therapeutics
650-327-3270





Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Nov. 8, 2011 MedBox (Pink Sheets: ... have changed their ticker symbol to MDBX.  The company ... to MedBox. The company is a ... dispensing systems of prescription medicines. The free-standing unit features ...
... 8, 2011 Reportlinker.com announces that a ... its catalogue: European Markets ... http://www.reportlinker.com/p0681077/European-Markets-for-Ophthalmic-Devices-2011-Diagnostic--Invasive.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Ophthalmic_Devices ... interventional ophthalmic device market was valued at ...
Cached Medicine Technology:MedBox Announces Ticker Symbol Change 2European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 2European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 3European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 4European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 5European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 6European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 7European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 8European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 9European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 10European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 11European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 12European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 13European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 14European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 15European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 16European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 17European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 18European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 19European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 20European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 21
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary research ... Kenis in the Institute of Genomic Biology (IGB) ... Urbana-Champaign describe their recent work on subcellular redox ... cell functions including energy metabolism, signaling, and transcriptional ... normal cellular behavior, redox status has been recognized ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
(Date:4/17/2014)... off depression among retirees, particularly among those who live ... The Journals of Gerontology, Series B: Psychological Sciences and ... Use and Depression Among Retired Older Adults in the ... that Internet use reduced the probability of a depressed ... , Late-life depression affects between 5 and 10 million ...
(Date:4/17/2014)... therapy improves general blood flow and alleviates muscle ... researchers at the University of Illinois at Chicago. ... print in the Archives of Physical Medicine ... vascular function in people who had not exercised, ... of their level of physical activity. , Improved ...
Breaking Medicine News(10 mins):Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2Health News:Massage therapy improves circulation, eases muscle soreness 2
... anti-reservation medicos strike in India, the government on Sunday night ... on quota in central educational institutes// but the students and ... by calling a bandh in Delhi on May 31. ... talks with Federal Minister Oscar Fernandes who followed it up ...
... attractive destination for conducting global clinical trials due to ... trained medical professionals and sophisticated technological infrastructure. // ... valued at Rs 3.1 billion in 2005 and is ... Most of the US and European nations are outsourcing ...
... Scientists in the US have created an artificial penis ... and may one day help treat men with severe ... Atala and colleagues at the Wake Forest Institute for ... new method of tissue engineering, reported the online edition ...
... city of Faisalabad have been affected by contaminated water, an ... victims of water-borne diseases, which broke out as a result ... to further increase as more people are being hospitalized., ... affected area is also underway. , ,'we have taken ...
... resolve of the students against reservations who continue their stir ... students tried to self immolate themselves - one in the ... whom the police described as a vendor, tried immolating himself ... gathered in strength, staged a rally protesting against the government's ...
... Geneva - The new interim head of the World Health ... first time since assuming office // , confirmed that Dr ... resources and the support from the people to continue the ... that he would continue the work of his predecessor Dr ...
Cached Medicine News:Health News:Two Students Try To Self-Immolate As Anti-Quota Stir Continues 2Health News:Two Students Try To Self-Immolate As Anti-Quota Stir Continues 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: